GlassScriptPhysician profile
Gregory M Wells
NPI 1265494181
$2,554.33
in general payments reported to CMS, 2019-2025
18 companies · $683 in 2025
The $683 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $19.33 · 2021: $135 · 2022: $261 · 2023: $505 · 2024: $818 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932 · Education: $74.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.89 |
| Education | $74.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $611.97 | 2022-2025 | Velphoro, Velphoro |
| Aurinia Pharma U.S., INC. | $409.00 | 2022-2024 | Lupkynis |
| Akebia Therapeutics INC | $366.57 | 2021-2025 | Vafseo, Auryxia |
| Astrazeneca Pharmaceuticals LP | $306.22 | 2020-2025 | Farxiga, Lokelma |
| Bard Peripheral Vascular, INC. | $133.34 | 2019 | |
| Travere Therapeutics, INC. | $121.14 | 2023-2025 | Filspari |
| Baxter Healthcare | $120.05 | 2022-2023 | Renal - Pd |
| Otsuka America Pharmaceutical, INC. | $74.67 | 2024-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $64.89 | 2023-2024 | Tarpeyo |
| Vifor Pharma, INC. | $63.33 | 2024-2025 | Veltassa |
| Novartis Pharmaceuticals Corporation | $62.97 | 2025 | |
| Scpharmaceuticals INC. | $46.44 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.49 | 2024 | |
| Amgen INC. | $40.92 | 2025 | Tavneos |
| Medtronic, INC. | $27.53 | 2025 | Symplicity G3 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $23.85 | 2024 | Ibsrela |
| Opko Pharmaceuticals, LLC | $20.16 | 2025 | Rayaldee |
| Hologic Sales and Service, LLC | $16.79 | 2024 | Novasure |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.